Tratamiento de pénfigo vulgar grave resistente con rituximab
| Autor: | José Pardo, Gerard Pitarch, Elena Roche, Arantxa Torrijos, José M. Fortea, J.L. Sánchez-Carazo |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Autoimmune disease
medicine.medical_specialty integumentary system business.industry Pemphigus vulgaris General Medicine medicine.disease Dermatology Infliximab Lymphoma Pemphigus immune system diseases hemic and lymphatic diseases Immunopathology medicine Rituximab skin and connective tissue diseases business Pemphigus foliaceus medicine.drug |
| Zdroj: | Actas Dermo-Sifiliográficas. 97:48-51 |
| ISSN: | 0001-7310 |
| DOI: | 10.1016/s0001-7310(06)73348-8 |
| Popis: | Pemphigus vulgaris is a potentially fatal autoimmune bullous disease. High doses of immunosuppressive drugs are used in managing severe cases of pemphigus. Rituximab, an anti-CD20 monoclonal antibody, has proven to be effective in patients with refractory pemphigus vulgaris and pemphigus foliaceus. We review cases of pemphigus vulgaris and pemphigus foliaceus not associated with lymphoma that were treated with rituximab, and we report a new case of severe refractory pemphigus vulgaris successfully treated with rituximab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect